Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context

The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 signalling in patients with the disease. The efficacy and safety of tocilizumab and sarilumab, which block the binding o...

Descripción completa

Detalles Bibliográficos
Autores principales: Angriman, Federico, Ferreyro, Bruno L, Burry, Lisa, Fan, Eddy, Ferguson, Niall D, Husain, Shahid, Keshavjee, Shaf H, Lupia, Enrico, Munshi, Laveena, Renzi, Samuele, Ubaldo, Onion Gerald V, Rochwerg, Bram, Del Sorbo, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078877/
https://www.ncbi.nlm.nih.gov/pubmed/33930329
http://dx.doi.org/10.1016/S2213-2600(21)00139-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078877/
https://www.ncbi.nlm.nih.gov/pubmed/33930329
http://dx.doi.org/10.1016/S2213-2600(21)00139-9

Ejemplares similares